AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02660411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60. Propofol infusion rate will be decreased towards the end of surgery. Propofol infusion will be stopped at the end of surgery.
Study NCT04713839 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: We didn't have an intervention program, we used two questionnaires to evaluate participants.
Study NCT03649061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept 50 MG/ML
Description: Etanercept 50mg subcutaneous (SC) weekly added for 24 weeks to COBRA-Slim scheme
Study NCT03649061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leflunomide 10 milligram (MG)
Description: Leflunomide 10mg PO daily added to the COBRA-Slim scheme
Study NCT02696538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Gait Assessment
Description: Balance assessment
Study NCT02696538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mini-Balance Evaluation Systems Test
Description: Balance assessment
Study NCT02696538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Berg Balance Scale
Description: Balance assessment
Study NCT01892410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cetaphil Restoraderm Skin Restoring Body Wash
Description: Diluted (10%) 0.2ml or 0.2g of Cetaphil on semi-occlusive, hypoallergenic patch applied to skin for 24 hrs 9 times on Monday, Wednesday, and Friday for 3 weeks
Study NCT01656330 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: Single 100 cc bolus of saline administered by intravenous (IV) injection on Day 5. Interpretation by CTRL: Concentration type = Exact ; Number = 100; unit=cc; route : intravenous use use.
Study NCT04545996 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Suboccipital Inhibition Technique
Description: Suboccipital Inhibition Technique For 2min And Conventional Treatment Hot Pack For 10 To 15 Mints And Muscle Energy Technique(Post Facilitation Stretch) 5 Reps × 1 Set Sessions: 2 TIME A WEEK FOR 4 CONSECUTIVE WEEKS
Study NCT03781635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bolus of intravenous ketamine
Description: low-dose ketamine (0.25mg.kg-1) is administered intraoperatively as bolus at incision (T0) and for each hour of anesthesia untel the end of surgery.
Study NCT03781635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: continuous infusion of intravenous ketamine
Description: An infusion of low-dose ketamine (0.25 mg.kg-1.h-1) is started at T0 (incision) with an infusion pump and is kept at the same rate until the end of surgery
Study NCT04134429 — intervention group
Intervention type: DEVICE
Intervention: Everion
Description: The Everion® device, by Biovotion, Zurich, is a on-skin wearable device measuring health data.
Study NCT02056041 — intervention group
Intervention type: PROCEDURE
Intervention: Hepatectomy
Study NCT02429661 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer support groups
Study NCT04545996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cranio Cervical Flexion Exercises.
Description: Cranio cervical flexion exercises10 repetitions for 10 seconds and conventional treatment hot pack for 10 to 15 mints and muscle energy technique(post facilitation stretch) 5 reps × 1 set Sessions: 2 TIME A WEEK FOR 4 CONSECUTIVE WEEKS
Study NCT06413251 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Boxing Training
Description: The boxing training intervention will consist of three exercise sessions per week on nonconsecutive days for six weeks. Participants will be instructed to complete 10 rounds of three minutes with a one-minute resting period interspersed. Four rounds will consist of heavy bag punching (e.g. straight, jab, hook) at 60% VO2max and three rounds at 90-95% VO2max, while the remaining 3 rounds will be focused on mitt work at 60% VO2max.
Study NCT06413251 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control flexibility
Description: The control group will perform three days per week 10 minutes of dynamic articular movement, five minutes of uni pedal stance, and five minutes of stretching of the upper limbs for six weeks.
Study NCT01891448 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WebCONSORT tool
Description: Authors are directed to the WebCONSORT tool. The tool allows authors to obtain a customized CONSORT checklist and flow diagram specific to their trial design (e.g., non-inferiority trial, pragmatic trial, cluster trial) and type of intervention (e.g., pharmacological or non pharmacological). The checklist items and flow diagram should then be reported in the manuscript and the completed checklist submitted to the journal along with the revision.
Study NCT01891448 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Modified WebCONSORT tool
Description: Authors are directed to a different version of the WebCONSORT tool. This tool includes the flow diagram part of the tool but not the main checklist or elements relating to CONSORT extensions.
Study NCT01965405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Participant will receive a prescription for Bupropion hydrochloride and will self-administer according to dosage instructions from the study psychiatrist.
Study NCT00549042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OROS hydromorphone
Description: hydromorphone 12, 16, 24, 32, 40, 48, or 64 mg tablets
Study NCT00549042 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01965405 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Counseling
Description: Participants are provided with brief counseling for smoking cessation.
Study NCT01965405 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-magnitude prize contingency management
Description: Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking.
Study NCT01965405 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monitored support to quit smoking
Description: Brief supportive sessions and monitoring of smoking cessation efforts.
Study NCT01965405 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No additional treatment
Description: No additional treatment will be given.
Study NCT01965405 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prize contingency management for abstinence
Description: Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking.
Study NCT01965405 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low intensity prize contingency management
Description: Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking.
Study NCT03760536 — intervention group
Intervention type: BEHAVIORAL
Intervention: 16-week Exercise Rehabilitation Program for Breast Cancer Survivors
Description: Interested patients will attend a group meeting where they will be screened and consented to the study. During weeks 1 and 2 patients will complete pre-intervention baseline assessments and blood draws followed by a 16-week supervised exercise program at Get REEL and HEAL facility. Study participants will complete progressive aerobic and resistance exercise training. Post-intervention weeks 1 and 2 participants will complete assessments, questionnaires and blood draws. Participants will be followed up at 6 and 12 months post intervention with physical assessments, questionnaires and blood draws. Annual follow-up will occur at year 2,3,4 and 5 post intervention with questionnaires only.
Study NCT03811184 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MemScreen
Description: Neuropsychological test on smartphone or digital tablet, on self assesment.
Study NCT04209816 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lipoprotein kinetics
Description: Lipoprotein kinetic apply protocol that endogenously label proteins and fatty acids with stable isotope-labeled amino acid and glycerol tracers. De novo lipogenesis is measured after ingestion of deuterated water to measure newly formed fatty acids in VLDL. Liver fat is measured with magnetic resonance spectroscopy and lipolytic enzymes with heparin test.
Study NCT03389568 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: singing-based music therapy program
Description: A single 1-hour singing-based intervention is conducted with each primary caregiver of an ICU patient. The intervention is composed of three steps: 1) listening to a participant's preferred music and identifying his and her emotional states (15 minutes), (2) singing for emotional changes (30 minutes), and (3) discussing what he or she experiences during singing and identifying how they apply such experience to their personal use of music for emotional changes in his or her everyday life (15 minutes).
Study NCT01747564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM178 (mirabegron)
Description: oral
Study NCT01337674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-4618
Description: Once daily oral dose of MK-4618 100 mg (two 50 mg tablets) on Days 1 through 7
Study NCT01337674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for MK-4618
Description: Once daily oral dose of placebo for MK-4618 100 mg (two 50 mg tablets) on Days 1 through 7
Study NCT01337674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: Previously prescribed daily dose of open-label metoprolol for the duration of the study
Study NCT01337674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Previously prescribed daily dose of open-label amlodipine for the duration of the study
Study NCT03662932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early intensive mobilization
Description: Early mobilization: mobilization with the hospital staff begins already on the day of surgery, and includes mobilization in and out of bed, rise up from a chair, standing and walking.~Intensive mobilization: mobilization more than 4 times a day in the first postoperative week.
Study NCT03646032 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SAAFE
Description: After completing the pre-game assessment, participants will be asked to play the SAAFE game for at least 30 minutes and up to 1 hour . At the conclusion of the game, participants will be provided with a post-game assessment about their perception of risk, knowledge of specific protective behaviors, and whether they plan to change behaviors.
Study NCT03646032 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: This group will receive dating sim game (called Choices). They will also receive pamphlets that provide information on the testing location and care if they have HIV/STI.
Study NCT03107078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Description: Intravenous Glucocorticoids (GCs)
Study NCT00006483 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Study NCT01089608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Eye drops, Dosage : 1.5%~1 drop twice daily at Day 0, then 1 drop once daily from Day 1 to Day 6 in the morning, following by a period of 2 weeks without treatment. This therapeutic scheme will be repeat 2 times.
Study NCT00664898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Escalating intravenous repeating dose
Study NCT00664898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-40
Description: Escalating intravenous repeating dose
Study NCT03348072 — intervention group
Intervention type: PROCEDURE
Intervention: Cardiac surgery
Description: Cardiac surgery
Study NCT01048892 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seneca Valley virus-001
Study NCT01048892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT01048892 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT01048892 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study NCT02660723 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Healthy Volunteers
Description: A catheter will be introduced in the arm vein and 14 ml of blood will be drawn in one 4 ml dry tube, one 5 ml heparinized tube for cell count and 5 1 ml TruCulture tubes.
Study NCT04635579 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood flow restriction
Description: Intervention restricts blood flow to the lower limb as a percentage of the limb occlusion pressure
Study NCT04635579 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blood flow restriction
Description: Intervention restricts blood flow to the lower limb as a percentage of the limb occlusion pressure
Study NCT02685722 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UC-MSCs Gel group
Description: This study for a six-month trials,Randomized, open, and parallel comparison before and after its own,Stage test includes screening stage, stochastic screening of more than a month difficult to heal wounds 20 people.By generating a random number of principle,Observation of UC-MSCs Gel group patients efficacy, safety and tolerability of selective parameter.
Study NCT02685722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gel group
Description: This study for a six-month trials,Randomized, open, and parallel comparison before and after its own,Stage test includes screening stage, stochastic screening of more than a month difficult to heal wounds 20 people.By generating a random number of principle,observed and compared Gel group patients may be no efficacy.
Study NCT04414579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Faster Insulin Aspart (Fiasp®)
Description: Subjects will be randomized either to use Fiasp or conventional insulin aspart in CSII. CSII settings (basal, bolus, and correction factors) will be optimized using a meal challenge for a 2-week run in period followed by a 10-week period of CSII use with the assigned insulin. After a 12-week maintenance period, each group will cross over to the other insulin (conventional insulin aspart or Fiasp) by CSII for a second 2-week optimization period followed by a 10-week treatment period.
Study NCT02384564 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu King Vision Video Laryngoscope aBlade
Description: At time of tracheal intubation, the subject will be intubated using the Ambu King Vision Video Laryngoscope with the appropriately sized Ambu aBlade System based on manufacturer guidelines and clinical judgement. The first attempt to successful intubation will be assessed. The Cormack Lehane and Percentage of Glottic Opening scores will be recorded via direct vision. Information on subsequent attempts, time to successful intubation, and ease of tracheal tube insertion will be assessed.
Study NCT02384564 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Laryngoscopy via Miller Straight Blade
Description: At time of tracheal intubation, the subject will be intubated via direct laryngoscopy using a straight laryngoscope blade, based on manufacturer guidelines and clinical judgement. The first attempt to successful intubation will be assessed. The Cormack Lehane and Percentage of Glottic Opening scores will be recorded via direct vision. Information on subsequent attempts, time to successful intubation, and ease of tracheal tube insertion will be assessed.
Study NCT03571958 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BMI
Description: A derivative of motivational interviewing (MI), which is a patient-centered, collaborative counseling approach to strengthen an individual's intrinsic motivation towards a positive behavior change. BMI is intended for healthcare providers with limited time (5-10 minutes) to support a positive behavior change.
Study NCT02160314 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pessary
Description: disposable, single-use pessary
Study NCT02160314 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Absorbent pad
Study NCT02543658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neostigmine Methylsulfate 1 MG/ML
Description: The initial dose was 1mg, intramuscular injection(IM) once every 12 hours. If there is no defecation after 12 hours, the dose is increased to 1mg IM once every 8 hours; if there is no defecation after 24 hours, the dose is increased to 1mg IM once every 6 hours. If the abdominal pressure drops below 12mmhg, neostigmine will be stopped, otherwise it will be used continuously for 7 days.
Study NCT02543658 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Conservative treatment
Description: Intragastric administration of paraffin oil, 50ml,once every 8 hours；gastrointestinal decompression with nasogastric tube and rectal tub; lycerin enema promotes defecation; patients with ascites undergo percutaneous puncture drainage. Other conservative medical treatment recommended by the guidelines.
Study NCT02543658 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Conservative treatment
Description: Intragastric administration of paraffin oil, 50ml,once every 8 hours；gastrointestinal decompression with nasogastric tube and rectal tub; lycerin enema promotes defecation; patients with ascites undergo percutaneous puncture drainage. Other conservative medical treatment recommended by the guidelines.
Study NCT01314989 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyproheptadine
Description: 0,25mg/kg/day orally in 2 doses per day (2mg/5 ml)for 1 month
Study NCT01314989 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: liquid placebo
Study NCT03576768 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real cTBS
Description: This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key)
Study NCT03576768 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham cTBS
Description: This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
Study NCT03576768 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real iTBS
Description: This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key).
Study NCT03576768 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham iTBS
Description: This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
Study NCT00184548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eptacog alfa (activated)
Description: Sterile, freeze-dried powder in single-use vials to be reconstituted with sterile water for injection.~Three doses of 200, 100 and 100 mcg/kg to be administered bolus i.v. (intravenous) over approx. three hours.
Study NCT00184548 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT04821479 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells (MSC)
Description: Intrathecal injections of autologous bone marrow derived mesenchymal stem cells
Study NCT02546830 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FreeO2 v2.2 active
Description: * Automatic adjustment of oxygen through the Free O2 device.~* FreeO2 device in mode medical data collecting(SpO2,EtCO2...).
Study NCT02546830 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FreeO2 v2.2 with manual oxygenation
Description: * Manual adjustment of oxygen without the assistance of the FreeO2 device.~* Only FreeO2 device in mode medical data collecting(SpO2,EtCO2...).
Study NCT01302431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manualised nurse-led telephone support
Description: The manualised nurse-led telephone support intervention is designed to provide proactive support and enable caregivers of people with multiple sclerosis manage problems encountered with caregiving
Study NCT04292782 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anterior Quadratus lumborum block
Description: ultrasound anterior quadratum lumborum block with 1 ml/kg 0.2% ropivacaine
Study NCT04292782 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: caudal block
Description: ultrasound guided caudal block with 1 ml/kg 0.2% ropivacaine
Study NCT03963154 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Embryonic Stem Cell Derived Retinal Pigment Epithelium (RPE)
Description: Implantation into one eye of hESC-derived RPE (Human Embryonic Stem Cell Derived Retinal Pigment Epithelium (RPE))
Study NCT02673398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment
Description: Ancillary studies
Study NCT02673398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02673398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Given PO